Clinical measures in transthyretin familial amyloid polyneuropathy-Reference-Cited by-同舟云学术

Clinical measures in transthyretin familial amyloid polyneuropathy

Published:2016-12-16 Issue:3 Volume:55 Page:323-332
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle Nerve

Author:

Coelho Teresa¹,Vinik Aaron²,Vinik Etta J.²,Tripp Tara³,Packman Jeff⁴,Grogan Donna R.⁴

Affiliation:

1. Hospital Santo Antonio, Centro Hospitalar do Porto, Largo Prof Abel Salazar; 4099-001 Porto Portugal

2. Eastern Virginia Medical School, Strelitz Diabetes Center; Norfolk Virginia USA

3. DM-Stat, Inc.; Malden Massachusetts USA

4. FoldRx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer, Inc.; Cambridge Massachusetts USA

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Neurology (clinical),Physiology

Reference41 articles.

1. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å;Blake;J Mol Biol,1978

2. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein;Monaco;Science,1995

3. Studies on thyroid hormone-binding proteins. II. Binding of thyroid hormones, retinol-binding protein, and fluorescent probes to prealbumin and effects of thyroxine on prealbumin subunit self association;Nilsson;J Biol Chem,1975

4. Transthyretin mutations in hyperthyroxinemia and amyloid diseases;Saraiva;Hum Mutat,2001

5. Fibril in senile systemic amyloidosis is derived from normal transthyretin;Westermark;Proc Natl Acad Sci USA,1990

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review;Frontiers in Neurology;2024-09-02

2. Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS);PLOS ONE;2024-01-19

3. Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey;Cardiology and Therapy;2023-12-20

4. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS);Orphanet Journal of Rare Diseases;2023-11-10

5. Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal;Orphanet Journal of Rare Diseases;2023-10-12